{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0054264\nAge: 89\nGender: Male\nSample ID: P-0054264-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Prostate Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 50.0%\n=============\nDNA Variants:\nALK c.3210_3249delinsA (p.M1071_L1083del) - in 25.00% of 1127 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nMYC - MYC (DUPLICATION)\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Inflammatory myofibroblastic tumor (IMT)\",\n    \"Disease Phase or Condition\": \"Refractory or unresectable ALK-positive IMT\",\n    \"Drug Name\": \"Crizotinib\",\n    \"Prior Treatment or Resistance Status\": \"Refractory or unresectable\",\n    \"Genomic Features\": \"ALK rearrangement (c.3210_3249delinsA, p.M1071_L1083del)\",\n    \"FDA-approval status\": \"FDA-approved for unresectable, recurrent, or refractory ALK-positive IMT in patients 1 year or older\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf\"\n  }\n}"
}